Literature DB >> 32823821

Protein Identification of Venoms of the African Spitting Cobras, Naja mossambica and Naja nigricincta nigricincta.

Ottilie Katali1, Loide Shipingana1, Peter Nyarangó1, Mirva Pääkkönen2, Erastus Haindongo1, Timothy Rennie1, Peter James2, John Eriksson2,3, Christian John Hunter1.   

Abstract

Cobra snakes, including Naja mossambica and Naja nigricincta nigricincta, are one of the major groups of snakes responsible for snakebites in southern Africa, producing significant cytotoxicity and tissue damage. The venom of N. mossambica has been briefly characterised, but that of N. n. nigricincta is not reported. The current study identifies the venom proteins of N. mossambica and N. n. nigricincta. This is achieved using sodium dodecyl sulphate (SDS)-polyacrylamide gel eletrophroresis (PAGE), followed by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Most of the proteins were less than 17 kDa in both snakes. N. mossambica was found to have 75 proteins in total (from 16 protein families), whereas N.n. nigricincta had 73 (from 16 protein families). Of these identified proteins, 57 were common in both snakes. The proteins identified belonged to various families, including the three-finger toxins (3FTx), Cysteine-rich secretory proteins (CRiSP), Phospholipase A2 (PLA2) and Venom metalloproteinase M12B (SVMP). The current study contributes to the profile knowledge of snake venom compositions, which is of fundamental value in understanding the proteins that play a major role in envenomation.

Entities:  

Keywords:  African spitting Cobras; Naja mossambica; Naja nigricincta nigricincta; antivenin; snake venom; snakebites

Mesh:

Substances:

Year:  2020        PMID: 32823821      PMCID: PMC7472217          DOI: 10.3390/toxins12080520

Source DB:  PubMed          Journal:  Toxins (Basel)        ISSN: 2072-6651            Impact factor:   4.546


1. Introduction

Snakebites are a major cause of morbidity and mortality in Africa, Asia and Latin America, [1,2], yet, a neglected tropical disease—mostly affecting remote and rural tropical regions [3,4,5]. The burden of snakebites has been estimated at 1.2 to 5.5 million per year worldwide [6], with about 400,000 victims ending up with permanent disabilities [2,7]. In Namibia, Southern Africa, 721 snakebites were recorded over the course of 12 months (August 2015 to July 2016) in the main referral hospital in the capital city, Windhoek [8]. These snakebites were caused by different snakes, including spitting cobra snakes, and a large proportion of the people bitten were children under the age of six-years-old—and many of these children suffered long-term disability [8]. Medically important Namibian spitting cobras include the Naja mossambica (Mozambique spitting cobra,) N. nigricollis (black-necked spitting cobra) and the N. nigricincta nigricincta (western barred spitting cobra or zebra snake), and its subspecies of N. nigricincta woodi (black spitting cobra) [9,10,11,12] (Figure 1). N. n. nigricincta is the most problematic.
Figure 1

The figure shows two common spitting cobras in Namibia under study: (a) Naja mossambica (Mozambique spitting cobra); (b) Naja nigricincta nigricincta (western barred spitting cobra or zebra snake). Photos courtesy of the Living Desert Snake Park (Angela Curtis and Stretch Cowbrink).

The limitation of medical facilities in rural areas makes it a challenge for snakebite victims who are often several hours away from the nearest health centre, and may not be equipped to effectively manage these medical emergencies [13,14]. Snakebite management is challenging as the identities of the snakes is not always known [15], and there is incomplete knowledge about best treatment practices. The choice of treatment in Namibia is usually limited to (1) supportive care, (2) a monovalent antivenin for confirmed Boomslang bites and (3) a polyvalent antivenin from the South African Institute for Medical Research (SAIMR) for any other snakebites [16]. The efficacy of the antivenins is highly dependent on the snake venom from which it is developed [17]. The SAIMR polyvalent antivenin is based on the venoms from ten snakes of viperine and elapids families (South African Vaccine Producers (PTY) Ltd., Gauteng, South Africa), and therefore, thought to be effective against those respective snakes [18,19,20,21]. However, the N. n. nigricincta venom is not included the production of this polyvalent. Locally, it has been observed that the polyvalent seem ineffective against the N. n. nigricincta, of which some local clinicians indicated that aggressive debridement is the cornerstone of snakebite management. In general, envenomations from these snakes cause severe cytotoxicity, necrosis, haemorrhage, anticoagulant and thrombolytic injuries, which may result in death [19]. These potent characteristics of envenomations are due to the venom compositions of the snakes. In general, the lyophilised venom compositions of numerous snakes are made up of 80% to 100% proteins and other non-protein components, including carbohydrates, lipids, amines, and inorganic salts [22]. Table 1 summarises the common protein families in various snake venoms and their functions. In elapids, the venom compositions mainly consist of two protein families: (1) Three-finger toxins (3TFxs), which are in highest abundance in most species and (2) the phospholipase A2s (PLA2s), which are the second most abundant [22]. The lyophilised venom composition of the N. mossambica from Tanzania has been characterised and is made up of 99% proteins, where ~69% are 3TFxs, ~27% are PLA2s, and ~3% are the snake venom serine proteases (SVSPs) [23]. The other ~1% of the venom is made up of endonuclease and unknown substances [23]. To our knowledge, the venom composition N. n. nigricincta has not been characterised. However, in animals, the N. n. nigricincta venom has been reported to possess haemorrhagic, necrotic, procoagulant and thrombolytic activities [13]. The present study aimed to profile the venom composition of N. mossambica and N. n. nigricincta from Namibia.
Table 1

This table summarises some of the common protein families found in various snake venoms, including elapids.

ProteinFamilyShort Description Mode of Action/Function MW (Kda)References
PLA2Esterases with a unique pancreatic loop at62–66 residues.Cleaves the sn-2 acyl bond to hydrolysephospholipids to release fatty acid and lyso-phospholipid.13–15[24,25]
3FTxsNon-enzymatic polypeptides consistingof 60–74 amino acids, of which threepeptide loops are stabilised by four orfive disulphide bridges.Mainly function as potent inhibitors of neuromusculartransmission, cardiac function andacetylcholinesterase. Moreover, interfere with nicotinic andmuscarinic acetylcholine receptors,acetylcholinesterase, ion channels, and cellmembranes.6–9[26,27,28,29,30]
SVMPs Monozinc endopeptidases.Not well understood, but in general, they inducehaemorrhage, inflammation, and apoptosis, whileinhibiting aggregation of platelets.20–100[31,32]
KUNDendrotoxins consisting of 57–60 aminoacids organised in a single polypeptidechain cross-linked by three disulfidebridges.Facilitate the release of the neurotransmitteracetylcholine at the neuromuscular junction, resultingin blockage of certain voltage-dependent K+ channelsin the nerve presynaptic terminals. [33]
LAAOFlavoenzymes found in acidic, neutraland basic forms.Not well understood but exist as homodimers whichcontribute the cytotoxic activities.50–70[34]
CRiSPSingle chain polypeptides containing 16cysteine molecules, of which ten areclustered in the C-terminal of thesequence.Act as inhibitors of cyclic nucleotide-gated channelsand L-type Ca2+ and/or K+ channels, to preventsmooth muscle contraction.20–30 [35,36,37]
NPs38 residue peptides with four prolineresidues, of which three are clustered inthe C terminal of the molecule.Diffuse into vascular smooth muscle cells to activateguanylate cyclase inducing vasodilation.[38,39]

Abbreviations: Phospholipase A2 (PLA2); Three finger toxins (3FTxs); Snake Venom Metalloproteinases (SVMPs); kunitz peptides (KUN); L-amino acid oxidases (LAAO); Cysteine-rich secretory proteins (CriSP); Natriuretic Peptides (NPs).

2. Results

The sodium dodecyl sulphate (SDS)-polyacrylamide gel eletrophroresis (PAGE) results indicated that most of the proteins were less than 17 kDa in both N. mossambica and N.n. nigricincta, as shown in cluster one (Figure 2).
Figure 2

This figure shows the SDS-PAGE of protein separation of the venoms of N. mossambica and N. n. nigricincta. The molecular weight marker (in kDa) is on the left of each venom sample for N. mossambica and N. n. nigricincta. The proteins were run in duplicates at 200 V for 40 min until the dye front reached the end of the six to 16% precast gel. The gels were silver-stained and digested with trypsin and analysed with HPLC-MS/MS.

The high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) raw data files were searched with Proteome Discoverer 2.2 software (Thermo Fisher Scientific, Waltham, MA, USA). Proteins which were identified with only one peptide were filtered out from the results. Only four and three proteins were identified when the N. mossambica and N. n. nigricincta venom samples were analysed without digestion, respectively. A total of 32 and 22 proteins, from N. mossambica and N. n. nigricincta respectively, were identified with in-solution digestion. However, the vast majority of the proteins were identified from in-gel digested samples (see Table 2). When all approaches were merged, a total of 75 and 73 proteins were identified for N. mossambica and N. n. nigricincta which belong to 16 families per snake. Of these, 57 were common to both snakes (see Figure 3 and Table 3). The mass of the proteins identified ranged from Individual 2.7 to 184.6 and 3.4 to 184.6 kDa for N. mossambica and N.n. nigricincta respectively (See Tables S1–S3). The quantity of the identified proteins was not determined.
Table 2

This table shows the number of proteins identified per approaches for the venoms of Naja mossambica and Naja nigricincta. nigricincta.

Method ApproachNumber of Proteins Per Species
N. mossambican (%) N. n. nigricintcan (%)
In-gel digestion (Silver-stained)71 (94.7)68 (93.2)
In-gel digestion (Not stained)54 (72.0)58 (79.5)
In solution digestion32 (42.7)22 (30.1)
No digestion4 (5.3)3 (4.1)
Figure 3

This figure shows the protein counts for N. mossambica and N.n. ningricincta venom and those common to both snakes.

Table 3

This table summarises the number of proteins identified for each protein family from the venoms of N. mossambica and N. n. nigricincta.

Protein Family Number of Proteins
N. mossambica N. n. nigricintca Common toBoth Snakes
5’-nucleotidase011
Cathelicidin200
Cystatin101
Cysteine-rich secretory protein (CRiSP)136
Flavin monoamine oxidase114
Glycosyl hydrolase 56020
Nerve growth factor (NGF-Beta)013
Nucleotide pyrophosphate/phosphodiesterase001
Ohanin/vespryn001
Peptidase S1001
Peroxiredoxin010
Phospholipase A2 (PLA2)116
Phospholipase B002
Three finger toxins (3FTx)10520
True venom lectin001
Venom complement C3 homolog003
Venom Kunitz-type family100
Venom metalloproteinase M12B (SVMP)117
Total181657

The number of proteins identified by four different approaches was pooled together to classify them into their respective families for N. mossambica and N. n. nigricincta venoms.

Three-finger toxins (3FTx) seemed to be the most abundant protein family, with 30 and 25 identified in N. mossambica and N. n. nigricincta, respectively. Various proteins were identified from the following families: Cysteine-rich secretory proteins (CRiSP), Phospholipase A2 (PLA2) and Venom metalloproteinase M12B (SVMP). Unique protein families identified in N. mossambica included cathelicidin and venom kunitz-type. On the other hand, glycosyl hydrolase 56 and peroxiredoxin families were only found in N.n. nigricincta (See Table 3 and Table S1). Prior to HPLC-MS/MS analysis, proteins were either subjected to silver stain in-gel digestion, (ii) no stain in-gel digestion, (iii) in-solution digestion, and (iv) no digestion. The percentage is relative to the total number of proteins from all approaches merged for N. mossambica (75 proteins) and N. n. nigricincta (73 proteins).

3. Discussion

The venoms of the cobra snakes N. mossambica and N.n. nigricincta are known to possess cytotoxic activity to their victims [13,19]—N. nigricincta is also reported to possess haemorrhagic, anticoagulant, and thrombolyt activity in animals [13]. The present study aimed to characterise the venoms of these cobra snakes in order to identify the specific proteins present. We carried out a bottom-up approach, however, acetonitrile precipitated proteins were analysed without digestion, in order to identify the protein complexity of the venoms of N. mossambica and N. n. Nigricincta. The protein complexity of the venoms of N. mossambica from Tanzania was previously characterised [23], while that of N. n. nigricincta, to our knowledge, is reported for the first time in the present study. In the current study, it is demonstrated that various proteins known to be responsible for pathological effects reported in various snake envenomation are also present in the two snakes, N. mossambica and N. n. nigricincta [22]. Moreover, the venom of the two snakes share more than 50% of the identified proteins. The majority of these proteins had a molecular mass of about 17 kDa and less (see Figure 2). Most proteins seemed to belong to the 3FTx family followed by CRiSP, SVMP and PLA2 and a couple from other families (see Table 3 and Table S1). However, this is the first study on the venom profile of N. n. nigricincta, similar protein families were reported by Petras et al. [23] for the venom of N. mossambica with the exemption of endonuclease family, of which our current study did not record. In addition, 12 more other protein families were identified for N. mossambica in the present study (Table 3). The variation among studies in protein identification may be due to the difference in the geographical location of the snakes. Moreover, Petras et al. [23] identified proteins from the Nawaprin family in the venom of N. nigricollis from Nigeria, Togo, and Cameroon, but not in that of the Tanzanian, which again may be due to different geographical locations. Due to the complexity of snake venom proteins, only a fraction of proteins and peptides can be identified in a single run of LC-MS/MS [40,41]. Hence, the experimentation of such complex samples is very critical, and the differences in techniques may result in variations among the analysis. In order to produce a high-throughput protein identification. The current study used four sample preparation methods incorporated with HPLC-MS/MS analysis (see Table 2), of which each method gave only a fraction of the total proteins identified. For instance, in N. n. nigricincta, the fragment cysteine-rich venom protein mossambin (accession, P0DL16) and cytotoxin Vc-5 (accession, Q9PS34) were only identified with the in-solution digestion approach. Whereas, basic phospholipase A2 nigexine (accession, P14556) was only identified with the silver-stained in-gel digestion method (See Table S4). Furthermore, the precursor ion exclusion list consisting of all identified proteins in preceding runs was used to analyse HPLC-MS/MS analysis output for the no stain in-gel digestion method. This method eliminated redundant proteins of high abundance, allowing identification of new and unique proteins that were missed in the first run. For example, c-type lectin galactose-binding isoform (accession, D2YVI2) and cytotoxin SP13b (accession, P60306) were identified only after the subjection of the exclusion list. Thus, the use of different sample preparation methods and replicated runs, coupled with the exclusion list, improved the comprehensiveness of protein analysis (See Table S3). There have been several monovalent and polyvalent antivenins used for cross neutralisation of snake envenomations [18,42]. The efficiency of the antivenin is highly dependent on the snake venom, on which it is based [17]. The South African Institute for Medical Research (SAIMR) polyvalent antivenin is the most commonly used in Africa [16,18], which has been used for cross neutralisation of the venom for more than 35 years [19]. In Namibia, most N.n. nigricincta envenomation incidences treated with this antivenin have been recorded to undergo radical excision around the site of the snakebite [43]. The treatment of these envenomations is done using the SAIMR polyvalent [16], of which N.n. nigricincta is not considered in its preparation [18,43]. Another example of ineffective antivenin has been reported by Sintiprungrat et al. [13], where the antivenin produced against the Indian N. naja was less effective against the Sri Lankan N. naja. The composition of the venom from these species has geographical intra-specific variations [17].

4. Conclusions

In conclusion, even though the composition of the proteins was not quantified, the venoms of the two cobra snakes N. mossambica and N.n. nigricincta have been successfully profiled, revealing a vast spectrum of proteins. The current study proposes further characterisations of these venoms for quantification to better understand these proteins, their toxicity and even therapeutic candidacy.

5. Materials and Methods

5.1. Snake Venom Samples

The venoms were milked from each adult N. mossambica and N.n. nigricincta and were lyophilised, yielding 95.3 and 129.2 mg, respectively [13]. These crude venom samples were stored at −20 °C until experimentation. The study was approved by National Commission on Research Science and Technology of Namibia through the University of Namibia (Certificate: RCIV00022018) and the exportation of samples to the Turku Bioscience Centre, Finland was permitted by the Namibian Ministry of Environment and Tourism (Permit: 118430).

5.2. Venom Protein Separation by SDS-PAGE and In-Gel Digestion

Crude venoms were dissolved in Laemmli buffer (one mg in 200 µL). From these samples, 50 µL were then separated by SDS-PAGE in six to 16% precast gel (Bio-Rad, Hercules, CA, USA). This was run at 200 V for 40 min until the dye front reached the end of the gel, was silver-stained, and cut into 16 pieces for a lane. Another gel was run under similar conditions except it was only allowed to run for 5 cm into the resolving gel and was not stained. These gels were digested using trypsin enzyme as described previously [44,45,46].

5.3. Acetonitrile Precipitation and In-Solution Digestion

Proteins (>10 kDa) were removed from the venom samples by acetonitrile precipitation. One mg of a dry venom sample was dissolved in 200 µl 80% acetonitrile, and then centrifuged for six minutes at 5000 relative centrifugal force (rcf). The supernatants containing peptides and small proteins were dried in SpeedVac. Dried supernatants were dissolved in 0.1% formic acid, and protein concentrations were determined with NanoDrop. In order to be able to detect also the possible small proteins and natural peptides in the venom samples, and not only tryptic peptides, each supernatant sample was divided into two portions. One portion of each sample was run with HPLC-MS/MS without carrying out digestion before the analysis. In order to analyse the tryptic peptides, the second portion of each sample was in-solution digested by reconstituting the sample to six M urea in 50 mM Tris-HCl (urea was used to denaturate the protein structure), reduced with 200 mM 1,4-dithiotreitol, alkylated using 200 mM iodoacetamide, and digested with trypsin (1:30 trypsin:substrate ratio) overnight at 37 °C. After digestion proteins were desalted using Sep-Pak C18 cartridges (Waters Corporation, Milford, MA, USA) and dried in SpeedVac.

5.4. LC-ESI-MS/MS Analysis

The tryptic peptide samples were then re-suspended into 0.1% formic acid so that a theoretical protein concentration was 3 µg/µL for each sample. The samples were further diluted in a ratio 1:15, so that theoretically 200 ng of each sample was injected into a nanoflow HPLC system (Easy-nLC1200, Thermo Fisher Scientific, Bremen, Germany) coupled to the Q Exactive HF (Thermo Fisher Scientific, in-gel digested samples) or to the Q Exactive mass spectrometer (Thermo Fisher Scientific, in-solution digested samples and concentrated gel samples) equipped with a nano-electrospray ionisation source. Peptides were first loaded on a trapping column and subsequently separated inline on 15 cm C18 column (75 µm × 15 cm, ReproSil-Pur 5 µm 200 Ã C18-AQ, Dr. Maisch HPLC GmbH, Ammerbuch-Entringen, Germany); the mobile phase consisted of water with 0.1% formic acid (solvent A) and acetonitrile/water (80:20 (v/v)) with 0.1% formic acid (solvent B); the active gradient lengths used depended on the complexity of the sample ranging between 10 to 120 min. The flow rate was set at 300 nL/min. Concentrated gel samples were first run using data-dependent acquisition method. In order to increase the number of identifications, precursor ions of identified peptides were added to mass exclusion list, and samples were re-run with mass spectrometer. This was repeated once. When creating the exclusion lists, precursor mass tolerance was set to ± 8 ppm, fragment mass tolerance to at ± 0.02 Da, maximum missed cleavages was set to two. Only precursors with high or medium confidence were selected for the exclusion lists. A significance threshold of p < 0.05 was used. No replicate runs were made on other samples.

5.5. Data Analysis

For data analysis, raw data were processed using Proteome Discoverer 2.2 (Thermo Fisher Scientific). The software was connected to an in-house server running the Mascot 2.6.1 software (Matrix Science). Data were searched against a custom-made venom database and target decoy database. The venom database was downloaded from UniProt (28.6.2018) and contained 6328 protein sequences from 655 different venomous species (See Table S4). In Proteome Discoverer MS/MS peptide mass tolerance was set at ± 8 ppm, fragment mass tolerance at ± 0.02 Da and the maximum missed cleavages was set to two. Carbamidomethyl (C) was chosen as a static modification. Oxidation (M) and acetyl (protein N-terminus) were chosen as dynamic modifications. Trypsin was selected as enzyme for digested samples. The non-digested samples were searched with ‘none’ selected as the enzyme. The Fixed Value, PSM validator node, was used to assign confidence to PSMs based on fixed score threshold of 0.05. Only protein with high or medium confidence are listed in this paper, and all identifications are based on at least two peptides per protein. A significance threshold of p < 0.05 was used. The processed data were exported as Microsoft Excel files and proteins which were identified with only one peptide were filtered out from the results and those that did not match the database were not identified. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [47] partner repository with the dataset identifier PXD020411.
  41 in total

1.  Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide.

Authors:  Horng H Chen; John G Lainchbury; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2002-09-18       Impact factor: 24.094

Review 2.  Structure and function of snake venom cysteine-rich secretory proteins.

Authors:  Yasuo Yamazaki; Takashi Morita
Journal:  Toxicon       Date:  2004-09-01       Impact factor: 3.033

Review 3.  L-amino acid oxidase from snake venom and its anticancer potential.

Authors:  Kok Keong Tan; Boon Huat Bay; Ponnampalam Gopalakrishnakone
Journal:  Toxicon       Date:  2018-02-04       Impact factor: 3.033

Review 4.  The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals.

Authors:  Adi Lahiani; Ephraim Yavin; Philip Lazarovici
Journal:  Toxins (Basel)       Date:  2017-03-16       Impact factor: 4.546

5.  Snakebite envenoming.

Authors:  Christian John Hunter; Karl-Heinz Piechazek; Peter Mokua Nyarang'o; Timothy Rennie
Journal:  Lancet       Date:  2019-01-12       Impact factor: 79.321

6.  Complete amino acid sequence of an acidic, cardiotoxic phospholipase A2 from the venom of Ophiophagus hannah (King Cobra): a novel cobra venom enzyme with "pancreatic loop".

Authors:  M Z Huang; P Gopalakrishnakone; M C Chung; R M Kini
Journal:  Arch Biochem Biophys       Date:  1997-02-15       Impact factor: 4.013

7.  Snakebite is Under Appreciated: Appraisal of Burden from West Africa.

Authors:  Abdulrazaq G Habib; Andreas Kuznik; Muhammad Hamza; Maryam I Abdullahi; Basheer A Chedi; Jean-Philippe Chippaux; David A Warrell
Journal:  PLoS Negl Trop Dis       Date:  2015-09-23

8.  Quantitative Characterization of the Hemorrhagic, Necrotic, Coagulation-Altering Properties and Edema-Forming Effects of Zebra Snake (Naja nigricincta nigricincta) Venom.

Authors:  Erick Kandiwa; Borden Mushonga; Alaster Samkange; Ezequiel Fabiano
Journal:  J Toxicol       Date:  2018-10-24

9.  The PRIDE database and related tools and resources in 2019: improving support for quantification data.

Authors:  Yasset Perez-Riverol; Attila Csordas; Jingwen Bai; Manuel Bernal-Llinares; Suresh Hewapathirana; Deepti J Kundu; Avinash Inuganti; Johannes Griss; Gerhard Mayer; Martin Eisenacher; Enrique Pérez; Julian Uszkoreit; Julianus Pfeuffer; Timo Sachsenberg; Sule Yilmaz; Shivani Tiwary; Jürgen Cox; Enrique Audain; Mathias Walzer; Andrew F Jarnuczak; Tobias Ternent; Alvis Brazma; Juan Antonio Vizcaíno
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

10.  Elapid snake venom analyses show the specificity of the peptide composition at the level of genera Naja and Notechis.

Authors:  Aisha Munawar; Maria Trusch; Dessislava Georgieva; Diana Hildebrand; Marcel Kwiatkowski; Henning Behnken; Sönke Harder; Raghuvir Arni; Patrick Spencer; Hartmut Schlüter; Christian Betzel
Journal:  Toxins (Basel)       Date:  2014-02-28       Impact factor: 4.546

View more
  1 in total

1.  The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra (Naja Species) Venoms.

Authors:  Abhinandan Chowdhury; Matthew R Lewin; Christina N Zdenek; Rebecca Carter; Bryan G Fry
Journal:  Front Immunol       Date:  2021-10-07       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.